Intracellular Delivery of Anti-SMC2 Antibodies against Cancer Stem Cells
Sara Montero‐Herradón(Universitat Autònoma de Barcelona), Simó Schwartz(CIBBIM-Nanomedicine), Joaquin Seras‐Franzoso(Vall d'Hebron Institut de Recerca), Helena Xandri(Universitat Autònoma de Barcelona), Francesc Martínez-Trucharte(Universitat Autònoma de Barcelona), Ibane Abasolo(Unknown), Diego Arango(Unknown), Fernanda Andrade(Universidade do Porto), Mireia Vilar-Hernández(Universitat Autònoma de Barcelona), Manuel Quesada(Universitat Autònoma de Barcelona), Diana Rafael(University of Lisbon)
Cited by 33
Related Papers
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells
|British Journal of Cancer|2004|275
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases
|Advanced Drug Delivery Reviews|2013|237
Bacterial Inclusion Bodies: Discovering Their Better Half
|Trends in Biochemical Sciences|2017|181
Bacterial inclusion bodies: making gold from waste
|Trends in biotechnology|2011|173
Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes
|Microbial Cell Factories|2015|147